A Phase 1, Pharmacologic and Pharmacodynamic Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors
This study is a Phase 1 and pharmacologic dose-escalation trial of MM-121 + certain
anticancer therapies. The dose-escalation portion of the study employs a 3 + 3 design to
assess the safety, tolerability, and pharmacokinetics of MM-121 administered weekly in
combination with certain anticancer therapies in patients with advanced/recurrent cancer.
Doses of MM-121 will be escalated when given in combination with a fixed dose of anticancer
therapy in this study until either the MTD is identified or the combination is shown to be
tolerable at the highest planned doses.
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Number of dose limiting toxicities (DLTs) within a cohort
Victor Moyo, MD
United States: Food and Drug Administration
|Albany, New York 12208|
|Cleveland, Ohio 44195|
|Philadelphia, Pennsylvania 19104|